{"id":5886,"date":"2025-02-12T14:28:01","date_gmt":"2025-02-12T14:28:01","guid":{"rendered":"https:\/\/integratedcarejournal.com\/?p=5886"},"modified":"2025-02-12T14:28:50","modified_gmt":"2025-02-12T14:28:50","slug":"managing-the-rising-tide-of-polypharmacy","status":"publish","type":"post","link":"https:\/\/integratedcarejournal.com\/managing-the-rising-tide-of-polypharmacy\/","title":{"rendered":"Managing the rising tide of polypharmacy"},"content":{"rendered":"
The increasing costs, complexities and clinical safety risks associated with polypharmacy make it an important issue for the NHS to address in 2025.<\/strong><\/p>\n Around 40 per cent of people over 65 are on five or more medications today. Of these, between 10 per cent and 30 per cent experience adverse drug reactions, and nearly half are non-adherent. It is thought that the cost of adverse drug reactions alone could exceed \u00a32.2 billion per year, while \u00a3300 million is wasted annually on unused medicines.1<\/sup> Thousands of preventable hospital admissions also happen every year due to complications related to medicines.<\/p>\n These numbers are likely to rise further as our population ages over the next few decades \u2013 so how do we start to manage this rising tide of polypharmacy and prevent more cases of harmful overprescribing in the years ahead?<\/p>\n Optum recently facilitated a workshop at the HSJ\u2019s ICS Medicines Forum, bringing together healthcare professionals from across England to explore the challenges and potential solutions.<\/p>\n What became clear is that polypharmacy is a complex, multi-faceted issue \u2013 and that there are no quick fixes. However, our discussions did arrive at five strategic challenges that need to be addressed.<\/p>\n These are discussed fully in our new white paper Connecting the dots: Action on polypharmacy and overprescribing \u2013 this blog provides a brief overview of each challenge.<\/p>\n 1. The technology challenge – delivering a more connected picture for practitioners<\/strong><\/p>\n First, we heard that one of the biggest challenges that practitioners face is accessing comprehensive, up-to-date patient information. When there is poor join-up between different healthcare record systems, it can be difficult for pharmacists and other primary care and community-based teams to get a full picture of a patient\u2019s medication history, particularly when patients are treated across multiple settings.<\/p>\n Delegates therefore called for a new generation of digital solutions that enable better integration of patient information across different care settings. This would give pharmacists a more joined up and connected picture of the patient\u2019s clinical history, making it easier to assess whether changes to a patient\u2019s medication are necessary. Mobile technologies for community-based teams were also felt to be essential for putting this information into the hands of those working remotely.<\/p>\n 2. The data challenge – setting the parameters for success across the system<\/strong><\/p>\n Linked to this, many respondents also highlighted difficulties getting hold of reliable and meaningful data to shape decision-making. This was sometimes due to incomplete or inaccurate reporting, or technical challenges involved in navigating IT systems to drop down the right data. In some cases, practitioners also resorted to collecting their own data manually via spreadsheets \u2013 a \u2018make-do-and-mend\u2019 approach because they couldn\u2019t access the right tools to help them.<\/p>\n At the other end of the spectrum, there was also concern about data overload, with too many competing dashboards and datasets. This led to an important discussion about how we develop a meaningful and consistent way of describing what success looks like and how we measure it. As well as improving data systems and tools, the conclusion therefore was that we need more consistent ways of measuring impact, specifically by agreeing common metrics to assess whether interventions are delivering against a given strategy.<\/p>\n 3. The people challenge – putting patients at the heart of the process<\/strong><\/p>\n Deprescribing is a deeply human process involving sensitive, nuanced judgement calls to balance the risks and benefits of changing a person\u2019s medication. Practitioners need to understand the reasons behind a patient\u2019s medication use, their health goals, and their preferences so that they can arrive at a solution that\u2019s best for each individual.<\/p>\n In our discussions, we heard some inspiring examples of good practice \u2013 one that sticks out was the role of outreach professionals going into people\u2019s homes to address medication issues in a way that reflected not just clinical considerations but the wider social and environmental factors shaping their health. However, it\u2019s also clear that cultivating these deeper, human interactions to achieve personalised care becomes increasingly difficult when resources are strained.<\/p>\n Respondents described breakdowns in communication between healthcare professionals, particularly at point of transfer, resulting in conflicting advice or missed opportunity to deprescribe. They emphasised too that the process of deprescribing itself can also take time and energy to fulfil \u2013 and so, just as there is the New Medicines service to support patients on new medications, some questioned whether a Deprescribing Medicines service may be needed too.<\/p>\n 4. The pathways challenge – ensuring continuity of care<\/strong><\/p>\n A related challenge was the need for better continuity of care, particularly during transitions such as hospital discharge or in cases where patients straddle multiple care pathways. Delegates discussed the importance of having multidisciplinary teams (MDTs) and case management models to ensure better coordination.<\/p>\n Regular structured medication reviews (SMRs) were deemed critical for ensuring that medication is optimised as patients move through the system, while stronger communication between healthcare professionals and close monitoring during transitions were needed to help patients get the joined-up care they need.<\/p>\n To achieve this, delegates felt that funding and contractual models needed to be better aligned with the goal of reducing overprescribing and improving medication safety, so that organisations are incentivised to support patients throughout their care journey.<\/p>\n 5. The training challenge – enhancing deprescribing skills<\/strong><\/p>\n Finally, some professionals felt underprepared to manage polypharmacy and overprescribing challenges effectively. As one delegate put it during the conference: \u201cPharmacists are taught how to prescribe, but not how to deprescribe.\u201d<\/p>\n Respondents highlighted the need for more robust training that focused not just on the clinical aspects of deprescribing, but on strengthening the interpersonal skills necessary to support shared decision-making with patients. Practitioners, in short, needed the right knowledge and capability to determine when deprescribing is appropriate, understand its impact, and identify and engage patients using population health management principles.<\/p>\n At Optum, we understand that technology alone won\u2019t solve all the challenges facing pharmacy and medicines management teams today. However, we believe that digital solutions can play a critical role in helping manage workload pressures and overcome some of the barriers preventing action on overprescribing.<\/p>\n Our Population360\u00ae product is designed to integrate with GP clinical records, helping pharmacy teams to rapidly stratify the patient population according to risk and identify patients who may benefit from proactive interventions. By streamlining these processes, Population360\u00ae allows pharmacy professionals to focus on helping patients get the most appropriate and effective medicines for their needs.<\/p>\n To find out more about how Population360\u00ae<\/sup> can support your organisation, contact us at askoptum@optum.com<\/a><\/strong><\/p>\n You can also download<\/a> our full white paper, Connecting the dots: action on polypharmacy and overprescribing<\/em><\/strong><\/p>\n This article was prepared by Sima Jassal<\/a> and Meera Parkash<\/a> in a personal capacity. The views, thoughts and opinions expressed by the author of this piece belong to the author and do not purport to represent the views, thoughts and opinions of Optum.<\/p>\nFive key challenges<\/h3>\n
How Optum can help<\/h3>\n
\n